These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 17621465

  • 1. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G, Zaffiri L, Ceccarelli G, Andreotti M, Massetti AP, Vella S, Mastroianni CM, Vullo V.
    HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
    Elion R, Cohen C, DeJesus E, Redfield R, Gathe J, Hsu R, Yau L, Ross L, Ha B, Lanier RE, Scott T, COL40263 Study Team.
    HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898
    [Abstract] [Full Text] [Related]

  • 6. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):530-4. PubMed ID: 17057610
    [Abstract] [Full Text] [Related]

  • 7. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE, COL30336 Study Team.
    HIV Clin Trials; 2003 Dec 15; 4(4):231-43. PubMed ID: 12916008
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M, Opravil M, von Wyl V, Hirschel B, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Battegay M, Yerly S, Günthard H, Bucher HC, Swiss HIV Cohort Study.
    AIDS; 2007 Oct 18; 21(16):2201-7. PubMed ID: 18090047
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
    Arrizabalaga J, Arazo P, Aguirrebengoa K, García-Palomo D, Chocarro A, Labarga P, Muñoz-Sánchez MJ, Echevarría S, Oteo JA, Uriz J, Letona S, Fariñas MC, Peralta G, Pinilla J, Ferrer P, Alvarez ML, Iribarren JA.
    HIV Clin Trials; 2007 Oct 18; 8(5):328-36. PubMed ID: 17956834
    [Abstract] [Full Text] [Related]

  • 12. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M, Staszewski S, Doerr HW.
    Antivir Ther; 2007 Oct 18; 12(5):695-703. PubMed ID: 17713153
    [Abstract] [Full Text] [Related]

  • 13. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS.
    HIV Clin Trials; 2006 Oct 18; 7(5):229-36. PubMed ID: 17162316
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R, Hidalgo C, Ríos MJ, Rivero A, Muñoz L, Lozano F, Gutiérrez-Ravé V, Gálvez MC, del Arco A, Santos J.
    Eur J Clin Microbiol Infect Dis; 2009 Apr 18; 28(4):399-402. PubMed ID: 18841401
    [Abstract] [Full Text] [Related]

  • 15. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.
    Cochrane Database Syst Rev; 2013 Jun 05; 2013(6):CD008270. PubMed ID: 23740608
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 17. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND, Bader J, Lejone TI, Ringera I, Puga D, Glass TR, Klimkait T.
    Trop Med Int Health; 2015 Jul 31; 20(7):914-8. PubMed ID: 25782332
    [Abstract] [Full Text] [Related]

  • 18. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study.
    J Infect Dis; 2005 Dec 01; 192(11):1921-30. PubMed ID: 16267763
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Bravenboer B, Ten Kate RW, Groeneveld P, Bierman W, van der Werf Ts, Gisolf E, Richter C.
    HIV Med; 2015 Feb 01; 16(2):122-31. PubMed ID: 25472825
    [Abstract] [Full Text] [Related]

  • 20. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
    d'Ettorre G, Mastroianni CM, Massetti AP, Lichtner M, D'Agostino C, Vullo V.
    AIDS; 2005 May 20; 19(8):841-2. PubMed ID: 15867503
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.